tbuckley/cabot-search huggingface dataset:
The impact of the Oncotype DX recurrence score pathology-clinical (RSPC) on the predicted recurrence risk for node negative breast cancer patients: A cancer center experience.
Authors: Barbara A. Wexelman, Alexander Gallagher, Barbara L. Smith, Steven J. Isakoff
Journal: Journal of Clinical Oncology (2014)

570 Background: The OncotypeDX 21-gene assay Recurrence Score (RS) is widely used to risk-stratify ER+, node negative breast cancer to determine the 10 year risk of distant recurrence (RR) and the potential benefit of chemotherapy. The OncotypeDX Recurrence Score Pathology-Clinical (RSPC) tool was recently developed to modify an individual’s RR by incorporating clinical and pathological features (age, tumor size, grade, and type of endocrine therapy). We evaluated the impact of the RSPC on the predicted RR in a cohort of patients (pts) at our institution. Methods: A retrospective chart review of the last 250 consecutive pts (2012-2013) at our institution with OncotypeDX RS was performed. RSPC was calculated and compared to the RR. Patients were excluded from analysis for the following: DCIS only, node positive, or in-breast recurrence. Low, intermediate (int), and high risk cut-offs were based on published data using RS <18 (RR<12%), RS 18-31 (RR 12-20%) and RS >31 (RR>20%). Results: Of 250 RS obtained, 166 (66.4%) met inclusion criteria for this analysis. Mean tumor size was 1.6 cm, median grade=2, mean age=55.6, 49.4% started Tamoxifen, and 14.5% received adjuvant chemotherapy. The mean RS was 15.2 (SD 7.7, range 0-48). The mean 10-year RR compared to RSPC was 10.2% vs 8.6% (p<0.001). In addition, 71.1%, 24.1%, and 4.8% of tumors had a low-, intermediate- and high-risk RS, compared to 81.9%, 14.5%, and 3.6% after RSPC adjustment. RR shifted as 29/40 (72.5%) int-RR pts were reclassified as low risk by RSPC, and 12/118 (10.2%) low-RR pts were reclassified to int/high risk, leading to a 40% decrease in the number of int-risk tumors. Small tumors (T1a/b) had the greatest decrease in RR (-3.2%), while 22 (21.4%) of T1c tumors dropped from int to low RR. Conclusions: The RSPC tool modified the RR by a small but statistically significant decrease in the predicted 10 year RR for ER+ node negative breast cancer in a single institutional cohort, with most intermediate RR tumors shifting to low RR. Although RSPC does not alter the predicted relative benefit of chemotherapy, adjustment for the absolute RR may alter absolute chemotherapy benefit and impact treatment choice.
Bortezomib, Melphalan and Low Dose TBI Conditioning for Patients Undergoing Autologous Stem Cell Transplantation for Multiple Myeloma
Authors: Francis K Buadi, Morie A. Gertz, Betsy R. Laplant, Alese Halvorson, Martha Q. Lacy, Suzanne R. Hayman, David Dingli, Prashant Kapoor, Wilson I Gonsalves, Teresa Miceli, Eva Brandes, Scott L Stafford, James A Martenson, William J Hogan, Shaji K. Kumar
Journal: Blood (2016)
Mortality rate and predictors of liver disease damage in histologically diagnosed Nonalcholic Steatohepatitis: a 15 years follow-up cohort study
Authors: A. Mangia, R. Santoro, V. Piazzolla, M.M. Squillante, D. Petruzzellis, E. Agostinacchio, M. Guido
Journal: Journal of Hepatology (2017)
Adipose tissue macrophages induce hepatic neutrophil recruitment and macrophage accumulation in mice
Authors: M. Bijnen, T. Josefs, I. Cuijpers, J. van de Gaar, M. Vroomen, E. Wijnands, S. Rensen, J.W. Greve, M. Hofker, E. Biessen, C. Stehouwer, C. Schalkwijk, K. Wouters
Journal: Journal of Hepatology (2017)
Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non–Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies
Authors: Thomas E. Stinchcombe, Ying Zhang, Everett E. Vokes, Joan H. Schiller, Jeffrey D. Bradley, Karen Kelly, Walter J. Curran, Steven E. Schild, Benjamin Movsas, Gerald Clamon, Ramaswamy Govindan, George R. Blumenschein, Mark A. Socinski, Neal E. Ready, Wallace L. Akerley, Harvey J. Cohen, Herbert H. Pang, Xiaofei Wang
Journal: Journal of Clinical Oncology (2017)

Purpose Concurrent chemoradiotherapy is standard treatment for patients with stage III non-small-cell lung cancer. Elderly patients may experience increased rates of adverse events (AEs) or less benefit from concurrent chemoradiotherapy. Patients and Methods Individual patient data were collected from 16 phase II or III trials conducted by US National Cancer Institute-supported cooperative groups of concurrent chemoradiotherapy alone or with consolidation or induction chemotherapy for stage III non-small-cell lung cancer from 1990 to 2012. Overall survival (OS), progression-free survival, and AEs were compared between patients age ≥ 70 (elderly) and those younger than 70 years (younger). Unadjusted and adjusted hazard ratios (HRs) for survival time and CIs were estimated by single-predictor and multivariable frailty Cox models. Unadjusted and adjusted odds ratio (ORs) for AEs and CIs were obtained from single-predictor and multivariable generalized linear mixed-effect models. Results A total of 2,768 patients were classified as younger and 832 as elderly. In unadjusted and multivariable models, elderly patients had worse OS (HR, 1.20; 95% CI, 1.09 to 1.31 and HR, 1.17; 95% CI, 1.07 to 1.29, respectively). In unadjusted and multivariable models, elderly and younger patients had similar progression-free survival (HR, 1.01; 95% CI, 0.93 to 1.10 and HR, 1.00; 95% CI, 0.91 to 1.09, respectively). Elderly patients had a higher rate of grade ≥ 3 AEs in unadjusted and multivariable models (OR, 1.35; 95% CI, 1.07 to 1.70 and OR, 1.38; 95% CI, 1.10 to 1.74, respectively). Grade 5 AEs were significantly higher in elderly compared with younger patients (9% v 4%; P < .01). Fewer elderly compared with younger patients completed treatment (47% v 57%; P < .01), and more discontinued treatment because of AEs (20% v 13%; P < .01), died during treatment (7.8% v 2.9%; P < .01), and refused further treatment (5.8% v 3.9%; P = .02). Conclusion Elderly patients in concurrent chemoradiotherapy trials experienced worse OS, more toxicity, and had a higher rate of death during treatment than younger patients.
Among Cirrhotic Patients with a Hepatitis C Sustained Viral Response, the Risk of De-novo Hepatocellular Carcinoma Relates to Baseline Factors and Not the Use of Direct Acting Antivirals: Results from a Nationwide Cohort
Authors: H. Innes, S.T. Barclay, P.C. Hayes, A. Fraser, J.F. Dillon, A. Stanley, A. Bathgate, S. McDonald, D. Goldberg, H. Valerio, R. Fox, N. Kennedy, P. Bramley, S.J. Hutchinson
Journal: Journal of Hepatology (2017)
Psychological well-being of caregivers influences the quality of life of advanced heart failure patients
Authors: LS Evangelista, KA Dracup, LV Doering, C Westlake, MA Hamilton, G Fonarow
Journal: Circulation (2001)

Psychological Well-Being of Caregivers Influences the Quality of Life of Advanced Heart Failure Patients Lorraine S Evangelista, Univ of California at Los ·Angeles, Los Angeles, CA; Kathleen A Dracup, 'Univ of California at San Francisco, San Francisco, CA; Lynn V Doering, Univ of California at Los Angeles, Los Angeles, CA; ·chery! Westlake, CA State Univ, Fullerton, CA; Michele A Hamilton, UCLA, Los Angeles, CA; Gregg_ Fonarow, Ahmanson Cardiomyopathy Clin, ·Univ of CA Med Ctr, Los Angeles, CA Caregivers of patients with chronic illness often experience psychosocial turmoil as their loved ones beoome increasingly incapacitated. However, there is a paucity of research that examines psychological well-being of caregivers and its impact on the quality of life (QOL) of patients with advanced heart failure (HF). We conducted this study to determine the levels of psychological well-being of caregivers and patients, describe perceived social support of patients, and identify patient and caregiver characteristics and psychological measures that predict QOL of patients. METHODS: Data were obtained from 103 patient-caregiver dyads. Psychological assessment included an evaluation of depression (Beck Depression inventory), perceived control (Control Attitude Scale), and QOL {SF-12). In addition, patients also completed the Medical Outcomes Study Social Support Questionnaire to measure perceived social support. Descriptive statistics were used to describe the demographic and psychological characteristics of the sample. Relationships between patient QOL, patient characteristics, and caregiver psychological well-being were assessed using univariate and multivariate analyses. RESULTS: Patients were 57.61 :t12.05 years, predominantly Caucasian (76.7%) and male (67%). Caregivers were 59.47+ 17.64 years, predominantly females (70.9%) and spouses of patients with advanced HF (80.6%). Patients reported minimal to moderate depression, moderate levels of perceived control over Illness and moderately low OOL. ·Caregivers experienced minimal depression, but moderately compromised QOL and perceived control. Patients felt that they had high levels of supoort. Regression analysis demonstrated that patients' age, employment status, and perceived social support and caregivers' perceived control and QOL accounted for 68% of the variance in patients' QOL. CONCLUSION: This study suggests that patients' perceived social support and caregivers' psychological well-being influences patients' QOL in the setting of advanced HF. Health· care workers must focus on supporting caregivers and providing them with strategies they need to support their· loved ones with advanced HF.
Antigen specific T cells induce significant changes in bile acid metabolism in a mouse model of cholangitis
Authors: B. Höh, F. Glaser, B. Engel, C. John, S. Weidemann, S. Stein, A. Carambia, A. Lohse, J. Herkel, J. Heeren, C. Schramm, D. Schwinge
Journal: Journal of Hepatology (2017)
Repopulation of tumor cells after neoadjuvant chemotherapy in non-small cell lung cancer and head and neck cancer: A neglected factor.
Authors: Shanlin Xu, Jinbo Yue, Jing Liu, Jia Yang, Jujie Sun, Dianbin Mu, Jinming Yu
Journal: Journal of Clinical Oncology (2013)

e18533 Background: Neoadjuvant chemotherapy (NAC) has been widely used to patients with locally advanced Non-Small Cell Lung Cancer (NSCLC) or Head and Neck Cancer(HNC).Less is known about repopulation in human cancer after chemotherapy. It is hypothesized that NAC might be the preceding stimulus to activate the epidermal growth factor receptor (EGFR), which may trigger cellular repopulation. We aim to ananlyze whether NAC could trigger repopulation of surviving cells and evaluate the potential role of EGFR in molecular mechanisms that underlie accelerated repopulation after chemotherapy. Methods: Fifty-two patients with locally advanced NSCLC (28 cases) and HNC(24 cases) were studied. received platinum-based NACImmunohistochemical expressions of ki67 and EGFR were measured from biopsy before NAC and surgical specimens after NAC. Spearman rank correlation analysis and Chi-square test was used to determine whether pretreatment clinicopathological characteristics and time between last day of last chemotherapy and surgery are predictive of tumor cells repopulation. Results: The median duration between the last day of last chemotherapy and surgery was 15 days (range, 1–53 days).Twenty-one (40%) of fifty-two patients showed an increased Ki67 proliferative index PI after chemotherapy.The increased PI were significantly associated with poor clinical response and longer interval between last chemotherapy and surgery. No significant relationship was found between the change of Ki67 and clinicopathological characteristics including the location of the tumor, clinical stage, and histological grade,as well as the change of EGFR expression. A delay greater than 14 days produced greater increases in Ki-67 change ( p =0.028) than lesser delays. Conclusions: Our results suggest that tumor cell repopulation may frequently occur in patients with longer interval,especially greater than 14 days between the last day of last chemotheraoy and surgery. Our results did not suggest a higher EGFR expression lead to increased proliferation.
Interferon Alfa and Dacarbazina (DTIC) in patients with disseminated malignant melanoma.
Authors: R.Nortilli Rnortilli, A.Molino Amolino, M.Turazza Mturazza, L.Sperotto Lsperotto, A.Bonetti Abonetti, G.L.Cetto Glcetto
Journal: Annals of Oncology (1992)
Impact of BRAF mutation and effectiveness of BRAF inhibitor on the brain metastases in patients with metastatic melanoma.
Authors: Tulasi Gummadi, Roxana Stefania Dronca, Chul Kim, Lisa A. Kottschade, Rajendar K Mittapalli, William F. Elmquist, Arkadiusz Dudek
Journal: Journal of Clinical Oncology (2013)

9048 Background: Brain metastases continue to be the major cause of morbidity and mortality in patients with metastatic melanoma. The impact of BRAF mutations and effectiveness of BRAF inhibitors on the brain metastases in these patients is lacking. Methods: Preclinical studies were conducted to assessthe steady-state brain and plasma distribution of vemurafenib, a BRAF inhibitor in FVB wild-type and Mdr1a/b-/-Bcrp1-/- mice deficient in the drug efflux transporters, p-glycoprotein (P-gp) and breast cancer resistant protein (BCRP). A retrospective analysis of patients with metastatic melanoma treated at University of Minnesota from August 2011 to December 2012 was conducted. A similar analysis of cases treated at Mayo Clinic is underway. Results: The preclinical studies in mice show that both P-gp and BCRP play a significant role in limiting the brain distribution of vemurafenib. Retrospective analysis was performed on 57 patients with Stage IIIc /IV cutaneous and mucosal melanoma. Patients with BRAF mutation had a higher incidence rate of brain metastases compared to patients without BRAF mutation, although it was not statistically significant (Incidence ratio=1.56; 95% CI=0.70-3.48; P=0.27). Vemurafenib neither reduced the incidence of brain metastases (Incidence ratio = 0.89; 95% CI: 0.30-2.60; P=0.83) nor made significant difference in overall survival. It was observed that treatment with BRAF inhibitor led to improvement in extracranial disease but did not affect progression of intracranial disease. Conclusions: In concordance with preclinical data which indicates that P-gp and BCRP play a significant role in limiting the brain distribution of vemurafenib, the retrospective analysis shows that there is improvement in extracranial disease but progression in intracranial disease with treatment with BRAF inhibitor in patients with metastatic malignant melanoma with BRAF mutation. Development of BRAF inhibitors that are not substrates for P-gp and BCRP or concomitant use of P-gp and BCRP inhibitors with vemurafenib, may be needed in order to control or prevent intracranial disease in these patients. Further analysis to improve statistical power of our observation is underway.
TRAF1 as a marker of exhaustion during chronic hepatitis C
Authors: E. Moreno, D. Subira, J. Miquel, E.S. de Villalobos, A.G. Praetorius, A. Madejon, A. Olveira, J. Garcia-Samaniego, A. Garcia, T. Parra, M. Romero, J.-R. Larrubia
Journal: Journal of Hepatology (2017)
Neoadjuvant endocrine therapy in locally advanced hormone receptor positive (HR+) breast cancer (BC) in a low-resource, middle-income setting (Guatemala).
Authors: Laila Saied Agrawal, Mei-Ling Pereira, Ingrid A. Mayer, Eduardo Gharzouzi
Journal: Journal of Clinical Oncology (2015)

e17594 Background: BC is the leading cause of cancer death in women in low- and middle-income countries (LMIC). For locally advanced BC, neoadjuvant treatment is often needed to downstage tumors prior to surgery, however many patients (pts) with BC in low-resource settings do not receive adequate therapy due to financial, social, and logistical barriers. This study evaluates the feasibility, adherence rates, and efficacy of neoadjuvant endocrine therapy with tamoxifen in a low-resource setting in Guatemala. Methods: This is a single arm, single center study of neoadjuvant tamoxifen in pts with locally advanced HR+ BC. Pts were treated with tamoxifen for 4-6 weeks then underwent a core biopsy of their primary tumor for Ki67 evaluation. If Ki67 was ≤ 10%, tamoxifen was continued for a total of 4 months. If Ki67 > 10%, pts were taken off study. The primary endpoint was assessing the proportion of pts who completed neoadjuvant treatment and received definitive surgery. Results: Of the 35 pts enrolled (Table), 32 (91.4%) returned for a biopsy after 4 weeks of tamoxifen. Seventeen pts were taken off study; 8 pts had Ki67 > 10% and 9 pts had clinical progression. Fifteen (46.9%) pts continued on tamoxifen for 4 months. Of these, 13 pts (86.7%) underwent mastectomy. By exam, 6 pts had a complete response (CR) and 7 pts had a partial response. There was one pathologic CR. One pt was lost to follow-up and in one the tumor was still too large. The cost of neoadjuvant endocrine therapy with additional biopsy was 28% the cost of neoadjuvant chemotherapy in this setting. Conclusions: Neoadjuvant tamoxifen is a tolerable, acceptable, and less expensive option for pts with HR+ locally advanced BC in a middle-income, low-resource setting, with good rates of adherence and clinical response. This has implications for other LMIC, but further studies are needed to better define patient selection, applicability, and length of treatment of neoadjuvant tamoxifen. Patient characteristics. Median age (years) 59 (35-78) Menopausal status Pre 9 Post 26 Histology Ductal 31 Lobular 3 Micropapillary 1 Clinical stage IIB 5 IIIA 22 IIIB 7 IIIC 1 Hormone status (IHC) ER+ 35 PR+ 29 HER2 (IHC) 0/1+ 32 2+ 1 3+ 2
Subcutaneous Low Dose Alemtuzumab: Role As a Salvage Therapy in Immune -Mediated Marrow Failure Conditions
Authors: Swapna Thota, Srinivasa Reddy Sanikommu, Bhumika Patel, Meena Sadaps, Cassandra M. Hirsch, Michael J. Clemente, Serena Marotta, Antonio M Risitano, Mikkael A. Sekeres, Jaroslaw P Maciejewski
Journal: Blood (2016)
Clinical and virological outcomes of hepatitis B virus inactive carriers and gray zone patients: a comparative analysis using current EASL and AASLD Guidelines criteria
Authors: M.S. Bonacci, S. Lens, Z. Mariño, M.C. Lodoño, S.P. del Pulgar, J. Costa, J.M. Sanchez-Tapias, X. Forns
Journal: Journal of Hepatology (2017)
Relapsed Nodular Lymphocyte-Predominant Hodgkin Lymphoma: An Analysis from the German Hodgkin Study Group (GHSG)
Authors: Dennis A. Eichenauer, Annette Pluetschow, Lena Schroeder, Michael Fuchs, Bastian von Tresckow, Volker Diehl, Peter Borchmann, Andreas Engert
Journal: Blood (2016)
NCCN Guidelines Insights: Hepatobiliary Cancers, Version 1.2017
Authors: Al B. Benson, Michael I. D'Angelica, Daniel E. Abbott, Thomas A. Abrams, Steven R. Alberts, Daniel A. Anaya, Chandrakanth Are, Daniel B. Brown, Daniel T. Chang, Anne M. Covey, William Hawkins, Renuka Iyer, Rojymon Jacob, Andrea Karachristos, R. Kate Kelley, Robin Kim, Manisha Palta, James O. Park, Vaibhav Sahai, Tracey Schefter, Carl Schmidt, Jason K. Sicklick, Gagandeep Singh, Davendra Sohal, Stacey Stein, G. Gary Tian, Jean-Nicolas Vauthey, Alan P. Venook, Andrew X. Zhu, Karin G. Hoffmann, Susan Darlow
Journal: Journal of the National Comprehensive Cancer Network (2017)

The NCCN Guidelines for Hepatobiliary Cancers provide treatment recommendations for cancers of the liver, gallbladder, and bile ducts. The NCCN Hepatobiliary Cancers Panel meets at least annually to review comments from reviewers within their institutions, examine relevant new data from publications and abstracts, and reevaluate and update their recommendations. These NCCN Guidelines Insights summarize the panel's discussion and most recent recommendations regarding locoregional therapy for treatment of patients with hepatocellular carcinoma.
Cannabinoid receptor 1 mediates M1 polarization of bone marrow-derived monocytes/macrophages via RhoA/NF-κB p65 and ERK1/2 signaling pathways respectively in mouse fibrotic liver
Authors: L. Tian, L. Yang, W. Li, X. Fan, J. Yang, N. Chang, J. Xie, L. Yang, L. Li
Journal: Journal of Hepatology (2017)
Direct acting antivirals improve neutrophil phagocytic capacity in chronic hepatitis C
Authors: B. Leber, A. Horvath, B. Schmerböck, M. Tawdrous, A. Streit, A. Posch, P. Fickert, W. Spindelböck, P. Stiegler, R.E. Stauber, V. Stadlbauer
Journal: Journal of Hepatology (2017)
FIB-4 variation in HIV/HCV co-infected patients treated with DAAs (direct-acting antivirals) with SVR12: a MaSTER cohort study
Authors: P. Nasta, M. Giralda, S. Odolini, L. Urbinati, F. Maggiolo, S. Digianbenedetto, N. Ladisa, M. Di pietro, A. Gori, F. Zacchi, F. Castelli
Journal: Journal of Hepatology (2017)
Validation of the ALBI grade as a substitute for the Child-Pugh class in the BCLC classification of hepatocellular carcinoma and of the additional value provided by the Neutrophil-to-Lymphocyte Ratio
Authors: M. Colombo, M.E. Burlone, M.T. Minh, R. Minisini, P. Giarda, D.J. PInato, M. Pirisi
Journal: Journal of Hepatology (2017)
Extracellular Vesicles in Metabolic Syndrome
Authors: M. Carmen Martínez, Ramaroson Andriantsitohaina
Journal: Circulation Research (2017)

Metabolic syndrome defines a cluster of interrelated risk factors for cardiovascular disease and diabetes mellitus. These factors include metabolic abnormalities, such as hyperglycemia, elevated triglyceride levels, low high-density lipoprotein cholesterol levels, high blood pressure, and obesity, mainly central adiposity. In this context, extracellular vesicles (EVs) may represent novel effectors that might help to elucidate disease-specific pathways in metabolic disease. Indeed, EVs (a terminology that encompasses microparticles, exosomes, and apoptotic bodies) are emerging as a novel mean of cell-to-cell communication in physiology and pathology because they represent a new way to convey fundamental information between cells. These microstructures contain proteins, lipids, and genetic information able to modify the phenotype and function of the target cells. EVs carry specific markers of the cell of origin that make possible monitoring their fluctuations in the circulation as potential biomarkers inasmuch their circulating levels are increased in metabolic syndrome patients. Because of the mixed components of EVs, the content or the number of EVs derived from distinct cells of origin, the mode of cell stimulation, and the ensuing mechanisms for their production, it is difficult to attribute specific functions as drivers or biomarkers of diseases. This review reports recent data of EVs from different origins, including endothelial, smooth muscle cells, macrophages, hepatocytes, adipocytes, skeletal muscle, and finally, those from microbiota as bioeffectors of message, leading to metabolic syndrome. Depicting the complexity of the mechanisms involved in their functions reinforce the hypothesis that EVs are valid biomarkers, and they represent targets that can be harnessed for innovative therapeutic approaches.
A Composite Event-Free Survival End Point to Evaluate Outcome after Allogeneic Transplantation for Severe Aplastic Anemia: A Study on Behalf of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)
Authors: Raynier Devillier, Hélène Labussière-Wallet, Laurence Clément, Ibrahim Yakoubagha, Jacques-Olivier Bay, Virginie Gandemer, Marie t Rubio, Anne Sirvent, Patrice Chevallier, Thierry Derevel, Sebastien Maury, Gerard Socie, Regis Peffault de Latour
Journal: Blood (2016)
The interpretation of follow-up 3D-magnetic resonance cholangiopancreatography/magnetic resonance imaging in patients with primary sclerosing cholangitis is difficult and highly variable even between experienced specialists
Authors: R. Zenouzi, J. Yamamura, S. Keller, C. Weiler-Normann, M. Sebode, A.W. Lohse, C. Schramm
Journal: Journal of Hepatology (2017)
High liver iron in biopsy of NAFLD patients is a predictor for cardiovascular and liver-related mortality
Authors: L. Stechemesser, M. Strasser, A. Feldman, M. Schranz, S. Zandanell, L. Denkmayr, S. Ruhaltinger, G. Strebinger, U. Huber-Schönauer, D. Niederseer, E. Müller, B. Paulweber, C. Datz, E. Aigner
Journal: Journal of Hepatology (2017)